- Home
- GLQ vs BDSX Comparison
GLQ vs BDSX Comparison
Compare GLQ & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLQ | BDSX |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 153.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLQ | BDSX |
|---|---|---|
| Price | $8.54 | $15.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 98.9K | 37.1K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 11.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $6.66 | $0.26 |
| 52 Week High | $8.73 | $20.21 |
Technical Indicators
Market Signals| Indicator | GLQ | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 56.06 |
| Support Level | $7.99 | $13.46 |
| Resistance Level | $8.55 | $16.66 |
| Average True Range (ATR) | 0.16 | 0.97 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 67.48 | 45.88 |
Price Performance
Historical ComparisonAbout GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.